Werner Enterprises Backs Innovative Hypertension Diagnostics Startup aTENSION.life with Strategic Funding

Innovative Diagnostics: A New Era for Hypertension Management

In a significant development for the life sciences sector, Dr. Werner Lanthaler, the founder and CEO of Wlanholding GmbH, is appointed Chairman of the Supervisory Board at aTENSION.life, a promising startup dedicated to enhancing precision diagnostics for hypertension. This strategic appointment aligns with a recent USD 3 million seed funding round led by Wlanholding, alongside eQventure and VP Venture Partners. The investment marks a crucial step for aTENSION.life, which aims to revolutionize the diagnosis and treatment of hypertension—a condition that affects approximately 1.3 billion adults worldwide, with a staggering 720 million individuals lacking adequate treatment due to underdiagnosis.

At the core of aTENSION.life's innovative approach is its proprietary ALDO+ technology platform, which enhances mass spectrometry-based diagnostics for patients with uncontrolled hypertension. The flagship product, ALDO+PA, specifically screens for primary aldosteronism, a condition that is often overlooked in 5-10% of hypertensive patients. Dr. Lanthaler highlights the critical importance of early and precise diagnoses, stating that this funding initiative significantly advances the company's goal of making clinical mass spectrometry diagnostics accessible to a broader patient population. Currently, the ALDO+PA test is available in Austria through a collaboration with labors.at, with plans for expansion into the DACH markets—Germany, Switzerland, and Austria—by 2026.

Under Dr. Lanthaler's strategic leadership, the management team of aTENSION.life, which includes CEO Bernhard Klemen, CSO Marko Poglitsch, and CBO Katharina Wieser, is well-positioned to make a significant impact in the healthcare landscape. Their focus on addressing the pressing global health issue of hypertension underscores a commitment to transforming innovative concepts into scalable solutions that improve patient outcomes. The initiative not only promises advancements in diagnostic capabilities but also aims to increase awareness and treatment options for a condition that significantly affects the quality of life for millions worldwide.

In addition to the recent funding and leadership changes, the collaboration with labors.at signifies a vital partnership that enhances the operational capabilities of aTENSION.life, enabling them to expand their testing services efficiently. This collaboration reflects the growing trend in the life sciences sector, where partnerships between startups and established laboratories are becoming increasingly essential for facilitating rapid growth and market entry.

The investment by Wlanholding further emphasizes its commitment to supporting high-tech sustainability and life sciences enterprises, which aligns with the broader industry goal of improving healthcare through technological innovation. As aTENSION.life moves forward with its ambitious plans, the implications for the management of hypertension and related health issues are profound, potentially leading to better patient care and improved public health outcomes.